Delivery Order SPE2DB22D9367-SPE2DB25FSZ69
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $29.3K on September 2, 2025, by the Defense Logistics Agency's Medical Supply Chain organization. The delivery order, which carries no set-aside designation, covers the supply of EYLEA 2 mg/0.05 ml syringes for delivery to Park Ridge, Illinois, with an ultimate completion date of September 23, 2025. EYLEA is a prescription...
- The Defense Logistics Agency awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a firm fixed-price delivery order valued at $24,446.00 for EYLEA 2 mg/0.05 mL syringes. The award, issued on July 31, 2025, with an ultimate completion date of August 21, 2025, does not utilize a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the...
- The U.S. Defense Logistics Agency has awarded a firm fixed-price delivery order contract worth $12,919.30 to DMS Pharmaceutical Group Inc., a woman-owned small business in Park Ridge, Illinois. The contract is for the delivery of EYLEA 2 MG/0.05 ML syringes, and has a completion date of February 28, 2024. This delivery order is part of a larger indefinite delivery contract, contract 4600082013 under the SPE2DB program, that DMS Pharmaceutical Group holds with the Defense Logistics Agency. The...
- The Defense Logistics Agency awarded a $5,027.12 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EYLEA 2 mg/0.05 ml vials. The contract, with an ultimate completion date of September 25, 2025, was issued without set-aside designation, allowing DMS to compete on its merits as a small business in the federal pharmaceutical marketplace. This delivery order falls under DMS...
- The U.S. Department of Defense's Defense Logistics Agency awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,761.76 contract is for the delivery of EYLEA 2 MG/0.05 ML VIAL 0.05ML, a medication, with a period of performance through September 23, 2024. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) that DMS Pharmaceutical Group...
- The U.S. government's Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $5,253.92 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of EYLEA 2 MG/0.05 ML VIAL 0.05ML, a pharmaceutical product, with a completion date of August 27, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group Inc. valued at up to...
- The Defense Logistics Agency awarded a $2,513.56 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Eylea 2 mg/0.05 ml vials. The delivery order, issued on September 3, 2025, with an ultimate completion date of September 24, 2025, represents a specialized pharmaceutical procurement under DLA's broader pharmaceutical supply mission. This award carries no set-aside designation,...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on September 3, 2025, for the supply of EYLEA 2 mg/0.05 ml vials totaling $25,135.40. This firm fixed-price delivery order, with an ultimate completion date of September 24, 2025, represents a discrete fulfillment under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA. The award carries...
- The Defense Logistics Agency awarded a $3,770.31 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for EYLEA 2 mg/0.05 mL vials on August 7, 2025, with an ultimate completion date of August 28, 2025. EYLEA is a prescription anti-vascular endothelial growth factor medication used to treat age-related macular degeneration and other retinal conditions. The contract was performed in Park Ridge, Illinois, where DMS Pharmaceutical Group maintains its headquarters. No set-aside...
- The Defense Logistics Agency issued a delivery order valued at $7,925.08 to DMS Pharmaceutical Group Inc. for EYLEA HD 8 mg/0.07 ml vials on July 25, 2025, with an ultimate completion date of August 15, 2025. EYLEA is a prescription pharmaceutical product used in the treatment of retinal diseases. This delivery order was issued under a firm fixed-price contract type with no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in...
- SPE2DB22D9367Indefinite Delivery Contract
- SPE2DB22D9367-SPE2DB25FSZ69Delivery Order
The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EYLEA 2 mg/0.05 ml syringes valued at $9,778.40. The award was made on September 10, 2025, with an ultimate completion date of October 1, 2025, under a firm fixed-price delivery order contract with no set-aside designation. Performance will take place at the contractor's Park Ridge facility. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency's SPE2DB program, a $499.9 billion vehicle established to support the comprehensive pharmaceutical supply needs of Department of Defense healthcare facilities worldwide. The contractor specializes in distributing branded and generic prescription drugs, biologics, and medical consumables to military and federal healthcare systems. EYLEA, a prescribed medication for treating retinal conditions, represents one of many specialty pharmaceutical products the contractor regularly supplies to federal agencies through this established procurement relationship.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.8k | 9/10/25 |